Investigation of the expressions of MMPs and TIMPs between isogeneic and allogeneic rat aortic transplantation

Wei,Si‑Dong; Cao,Ding; Xu,Xue‑Song; Bai,He; Wu,Hao; Wang,Meng‑Hao

doi:10.3892/mmr.2018.8684

Investigation of the expressions of MMPs and TIMPs between isogeneic and allogeneic rat aortic transplantation

Authors:
- Si‑Dong Wei
- Ding Cao
- Xue‑Song Xu
- He Bai
- Hao Wu
- Meng‑Hao Wang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, People's Hospital of Zhengzhou, Southern Medical University, Zhengzhou, Henan 450003, P.R. China, Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
Published online on: March 6, 2018 https://doi.org/10.3892/mmr.2018.8684
Pages: 6909-6913

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effects of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in transplantation-associated arteriosclerosis by observing their expression in transplanted aortas in rats. Allogenic and isogenic abdominal aortic transplantations were performed and grafts were removed from the recipients at the designated time points (day 7, 14, 28 and 56 post transplantation). Hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and western blot analysis were used to evaluate the grafts. Significant proliferation of the intima was observed in the allogenic transplantation groups (P<0.05). The expressions of MMPs and TIMPs in the allografts were significantly increased compared with the isografts, and the suppression of MMP2 in allografts reduced injury after transplantation. The present study concluded that the imbalance of MMPs and TIMPs led to the disturbance of synthesis and the degradation of the extracellular matrix and it may represent a key cause of chronic rejection.

View Figures

View References

1	von Rossum A, Laher I and Choy JC: Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. Front Immunol. 5:6842014.PubMed/NCBI
2	Rahmani M, Cruz RP, Granville DJ and McManus BM: Allograft vasculopathy versus atherosclerosis. Circ Res. 99:801–815. 2006. View Article : Google Scholar : PubMed/NCBI
3	Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 92:827–839. 2003. View Article : Google Scholar : PubMed/NCBI
4	Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
5	Sommer W, Knöfel AK, Izykowski N, Oldhafer F, Avsar M, Jonigk D, Warnecke G and Haverich A: Physical exercise reduces transplant arteriosclerosis in a mouse aorta transplantation model. J Thorac Cardiovasc Surg. 149:330–337. 2015. View Article : Google Scholar : PubMed/NCBI
6	Mitchell RN: Learning from rejection: What transplantation teaches us about (other) vascular pathologies. J Autoimmun. 45:80–89. 2013. View Article : Google Scholar : PubMed/NCBI
7	Dimas G, Iliadis F and Grekas D: Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches. Hippokratia. 17:292–297. 2013.PubMed/NCBI
8	Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N and Taketomi A: Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952. 2017. View Article : Google Scholar : PubMed/NCBI
9	Calautti E, Avalle L and Poli V: Psoriasis: A STAT3-centric view. Int J Mol Sci. 19:pii: E171. 2018.PubMed/NCBI
10	Solomon A, Li DQ, Lee SB and Tseng SC: Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci. 41:2154–2163. 2000.PubMed/NCBI
11	Lakatta EG: The reality of aging viewed from the arterial wall. Artery Res. 7:73–80. 2013. View Article : Google Scholar : PubMed/NCBI
12	Struewing IT, Durham SN, Barnett CD and Mao CD: Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J Biol Chem. 284:17595–17606. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wu WB and Huang TF: Activation of MMP-2, cleavage of matrix proteins and adherens junctions during a snake venom metalloproteinase-induced endothelial cell apoptosis. Exp Cell Res. 288:143–157. 2003. View Article : Google Scholar : PubMed/NCBI
14	Shapiro S, Khodalev O, Bitterman H, Auslender R and Lahat N: Different activation forms of MMP-2 oppositely affect the fate of endothelial cells. Am J Physiol Cell Physiol. 298:C942–C951. 2010. View Article : Google Scholar : PubMed/NCBI
15	Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z, Xing Q, Yin X, Maddaluno M, Drung B, Schmidt B, et al: Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. Arterioscler Thromb Vasc Biol. 34:90–98. 2014. View Article : Google Scholar : PubMed/NCBI
16	Austin KM, Nguyen N, Javid G, Covic L and Kuliopulos A: Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis. J Biol Chem. 288:23105–23115. 2013. View Article : Google Scholar : PubMed/NCBI
17	Hsieh JL, Shiau AL, Lee CH, Yang SJ, Lee BO, Jou IM, Wu CL, Chen SH and Shen PC: CD8⁺ T cell-induced expression of tissue inhibitor of metalloproteinses-1 exacerbated osteoarthritis. Int J Mol Sci. 14:19951–19970. 2013. View Article : Google Scholar : PubMed/NCBI
18	Raffetto JD and Khalil RA: Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 75:346–359. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ries C: Cytokine functions of TIMP-1. Cell Mol Life Sci. 71:659–672. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lambert E, Dassé E, Haye B and Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 49:187–198. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kashiwagi M, Tortorella M, Nagase H and Brew K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem. 276:12501–12514. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hubmacher D and Apte SS: ADAMTS proteins as modulators of microfibril formation and function. Matrix Biol. 47:34–43. 2015. View Article : Google Scholar : PubMed/NCBI